'Super gonorrhea' raises the stakes in the war against superbugs

There has been a lot of news over the past few weeks about the rise of superbugs and antibiotic overuse, including a nasty sexually transmitted infection in the United Kingdom. A British man is the first in the world to be diagnosed with a strain of gonorrhea resistant to all strains of antibiotics used to treat the infection. The Guardian reported that he contracted the infection from a sexual encounter with a woman in southeast Asia, but his partner in the UK tested negative for the disease. His case was diagnosed when he sought treatment earlier this year.

Untreated, gonorrhea can lead to complications including infertility, and it can make the transmission of HIV more likely.

Superbugs have tended to pose the greatest risk to people with compromised immune systems, such as cancer patients, and those who were injured or underwent surgery. But the sexual transmission of these bugs means antibiotic resistant infections can spread much more widely.

So what exactly are superbugs, and how scared should we be?

"Superbugs" aren't the bug equivalent of superheroes. The term describes bacteria that have become resistant to antibiotics. How "super" they are depends on how many antibiotics they have become resistant to.

>>Read more: CDC says drug-resistant 'nightmare bacteria' pose growing threat.

"Antibiotic resistance" and "drug-resistant infections" also refer to the same phenomena. They describe microorganisms that have evolved to become impervious to being killed by treatment with antibiotics.

There is a common misconception that antibiotic resistance means your body has become resistant to antibiotics. This is not true.

Antibiotic resistance is nothing new. Alexander Fleming's 1945 Nobel Prize acceptance speech for the discovery of penicillin discusses the development of resistance. He includes a scenario of Patient X, who "buys some penicillin and gives himself, not enough to kill the streptococci but enough to educate them to resist penicillin. He then infects his wife. Mrs. X gets pneumonia and is treated with penicillin. As the streptococci are now resistant to penicillin the treatment fails."

Indeed, resistance has been reported for every antibiotic ever introduced – generally within a few years of deployment.

Bacteria are able to fight antibiotics by a variety of methods:

One or more of these resistance mechanisms may already be naturally present in a very small fraction of the millions of bacteria exposed to an antibiotic. This is called "innate resistance". Most of the bacteria are killed, but this small population survives and grows.

In other cases, resistance develops through evolution (a process known as "induced resistance"). Bacteria grow rapidly. Under optimal conditions the population can double in as few as 15-30 minutes.

When exposed to sublethal doses of antibiotic, bacteria can become tolerant. They accumulate beneficial mutations over multiple generations. They then pass on this resistance to their progeny when they divide.

Bacteria are also very promiscuous. They exchange pieces of genetic material (plasmids) that carry the codes for resistance. This allows for the rapid spread of resistance between different types of bacteria.

An example is highlighted by recent news reports of resistance to a "last resort" antibiotic, colistin. A gene called mcr-1 (mobilized colistin resistance) was found to be contained in plasmids in E. coli bacteria collected from Chinese pig farms in 2011 (though it was not reported until 2015).

While colistin resistance was already known, the potential for resistance to be quickly spread by this new mechanism is of great concern. For some infections, colistin is the only antibiotic that still works. Indeed, the mcr-1 gene has now been found in multiple types of bacteria in more than 30 countries (including a patient in the United States in 2016).

The World Health Organisation is now warning that we face a return to a "pre-antibotic era". It warns that, "common infections and minor injuries which have been possible to treat for decades may once again kill millions. Resistance to antibiotics will make complex surgeries and management of several chronic illnesses like cancer extremely difficult."

Before antibiotics, 40 percent of deaths were due to infection. If we do not act, a review commissioned by the United Kingdom government predicts that by 2050 drug-resistant infections could cause 10 million annual deaths.

This rise in resistance is largely driven by excessive antibiotic use. The same UK report indicates that up to two-thirds of the world's antibiotics are not used to treat humans, but are given to animals grown for food. This animal use is often as a food additive, not as therapeutic treatment for an infection.

Of the remaining antibiotics used in humans, up to two-thirds may be inappropriately prescribed.

This huge overuse of antibiotics inevitably drives the development of resistance by unnecessarily exposing a much greater population of bacteria to antibiotics. Sub-lethal concentrations, such as in waste water from farms, fosters resistance.

Alarmingly, a recent study shows that our use of antibiotics is increasing even more.

So, given we already have people dying from bacteria resistant to all known antibiotics, and these bacteria are becoming increasingly prevalent, what's stopping a global pandemic tomorrow?

It really comes down to the fact that, unless you're immunocompromised or have an injury allowing the bacteria to get into your body, most bacteria aren't particularly effective at spreading infections.

This is why the reports of a "super-gonorrhea" case in the UK are alarming. The sexually transmitted bacteria (Neisseria gonorrhoeae) causes nearly 80 million infections a year. This bacteria now has the potential to carry and spread high levels of antibiotic resistance through a much larger population of both people and other bacteria.

It's not all doom and gloom. Nations and international organisations are increasingly devoting attention and resources to fight the rise of antibiotic resistance. Strategies include more sparing use of existing antibiotics, and investment and incentives to develop diagnostics that can decide when antibiotics are needed.

Non-antibiotic approaches, such as vaccines, phage therapy, and microbiome manipulation, are garnering increased consideration.

Initiatives to re-invigorate the discovery of new antibiotics include efforts such as The Global Antibiotic Research & Development Partnership, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, and Australia's own global effort to crowdsource antibiotics from international chemists, The Community for Open Antimicrobial Drug Discovery.

Mark Blaskovich, Senior Research Officer, The University of Queensland. This article was originally published on The Conversation. Read the original article.